PSG9 Inhibitors
The chemical class termed PSG9 inhibitors comprises a selection of compounds meticulously chosen to modulate the expression and function of PSG9, a protein intricately involved in DNA repair processes. Among these, A-1210477 emerges as a noteworthy inhibitor, specifically targeting the PARP family. PSG9, being intricately linked to DNA repair, is indirectly modulated by A-1210477 through inhibition of PARP. The compound's specificity for PARP ensures precise control over DNA repair pathways, subsequently influencing PSG9 expression and function. Olaparib, Niraparib, Talazoparib, Veliparib, and AZD2281 collectively represent PARP inhibitors within this chemical class. These compounds disrupt DNA repair mechanisms, impacting PSG9 as a downstream effector of the DNA repair pathways regulated by PARP. The specificity of each PARP inhibitor ensures selective control over DNA repair pathways, providing a nuanced approach to modulating PSG9 expression and function.
The topoisomerase inhibitors, including Camptothecin, Topotecan, Etoposide, Doxorubicin, and Mitoxantrone, exert their effects by disrupting DNA replication and repair. PSG9, intimately involved in DNA repair, is indirectly modulated by these inhibitors through their impact on topoisomerase enzymes. The broad influence of these compounds on DNA repair pathways ensures a comprehensive modulation of PSG9 expression and function. Cisplatin represents another avenue for PSG9 modulation within this class. Cisplatin impacts DNA repair processes, indirectly influencing PSG9 through alterations in DNA structure. The compound's influence on DNA repair pathways broadens the scope of PSG9 modulation, highlighting the diverse strategies within the PSG9 inhibitors chemical class.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
A-1210477 | 1668553-26-1 | sc-507474 | 5 mg | $195.00 | ||
A-1210477 is a selective inhibitor of the PARP family, impacting DNA repair mechanisms. By inhibiting PARP, A-1210477 indirectly modulates PSG9, as PSG9 is involved in DNA repair processes. The compound's specificity for PARP ensures precise control over DNA repair pathways, subsequently influencing PSG9 expression and function. | ||||||
Olaparib | 763113-22-0 | sc-302017 sc-302017A sc-302017B | 250 mg 500 mg 1 g | $210.00 $305.00 $495.00 | 10 | |
Olaparib is a PARP inhibitor disrupting DNA repair mechanisms. PSG9, involved in DNA repair, is indirectly modulated by Olaparib through inhibition of PARP. The compound's specificity for PARP ensures selective control over DNA repair pathways, influencing PSG9 expression and function. | ||||||
Niraparib | 1038915-60-4 | sc-507492 | 10 mg | $150.00 | ||
Niraparib is a PARP inhibitor impacting DNA repair processes. By selectively inhibiting PARP, Niraparib indirectly modulates PSG9, a protein involved in DNA repair. The compound's specificity for PARP ensures precise control over DNA repair pathways, subsequently influencing PSG9 expression and function. | ||||||
Talazoparib | 1207456-01-6 | sc-507440 | 10 mg | $795.00 | ||
Talazoparib is a PARP inhibitor disrupting DNA repair mechanisms. PSG9, involved in DNA repair, is indirectly modulated by Talazoparib through inhibition of PARP. The compound's specificity for PARP ensures selective control over DNA repair pathways, influencing PSG9 expression and function. | ||||||
Veliparib | 912444-00-9 | sc-394457A sc-394457 sc-394457B | 5 mg 10 mg 50 mg | $182.00 $275.00 $726.00 | 3 | |
Veliparib is a PARP inhibitor affecting DNA repair processes. By inhibiting PARP, Veliparib indirectly modulates PSG9, a protein involved in DNA repair. The compound's specificity for PARP ensures precise control over DNA repair pathways, subsequently influencing PSG9 expression and function. | ||||||
Camptothecin | 7689-03-4 | sc-200871 sc-200871A sc-200871B | 50 mg 250 mg 100 mg | $58.00 $186.00 $94.00 | 21 | |
Camptothecin is a topoisomerase I inhibitor disrupting DNA replication and repair. PSG9, involved in DNA repair, is indirectly modulated by Camptothecin through inhibition of topoisomerase I. The compound's impact on DNA repair pathways ensures a broad influence on PSG9 expression and function. | ||||||
Topotecan | 123948-87-8 | sc-338718 | 100 mg | $582.00 | ||
Topotecan is a topoisomerase I inhibitor impacting DNA replication and repair. By inhibiting topoisomerase I, Topotecan indirectly modulates PSG9, a protein involved in DNA repair. The compound's impact on DNA repair pathways ensures a broad influence on PSG9 expression and function. | ||||||
Etoposide (VP-16) | 33419-42-0 | sc-3512B sc-3512 sc-3512A | 10 mg 100 mg 500 mg | $51.00 $231.00 $523.00 | 63 | |
Etoposide is a topoisomerase II inhibitor disrupting DNA replication and repair. PSG9, involved in DNA repair, is indirectly modulated by Etoposide through inhibition of topoisomerase II. The compound's impact on DNA repair pathways ensures a broad influence on PSG9 expression and function. | ||||||
Doxorubicin | 23214-92-8 | sc-280681 sc-280681A | 1 mg 5 mg | $176.00 $426.00 | 43 | |
Doxorubicin is a topoisomerase II inhibitor impacting DNA replication and repair. By inhibiting topoisomerase II, Doxorubicin indirectly modulates PSG9, a protein involved in DNA repair. The compound's impact on DNA repair pathways ensures a broad influence on PSG9 expression and function. | ||||||
Mitoxantrone | 65271-80-9 | sc-207888 | 100 mg | $285.00 | 8 | |
Mitoxantrone is a topoisomerase II inhibitor disrupting DNA replication and repair. PSG9, involved in DNA repair, is indirectly modulated by Mitoxantrone through inhibition of topoisomerase II. The compound's impact on DNA repair pathways ensures a broad influence on PSG9 expression and function. | ||||||